Cargando…

Metabolomics Point out the Effects of Carfilzomib on Aromatic Amino Acid Biosynthesis and Degradation

(1) Carfilzomib (Cfz) is an antineoplastic agent indicated for the treatment of multiple myeloma. However, its beneficial action is attenuated by the occurrence of cardiotoxicity and nephrotoxicity as the most common adverse effects. Presently, there is well-established knowledge on the pathomechani...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barla, Ioanna, Efentakis, Panagiotis, Lamprou, Sofia, Gavriatopoulou, Maria, Dimopoulos, Meletios-Athanasios, Terpos, Evangelos, Andreadou, Ioanna, Thomaidis, Nikolaos, Gikas, Evangelos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10530946/ https://www.ncbi.nlm.nih.gov/pubmed/37762269 http://dx.doi.org/10.3390/ijms241813966

Ejemplares similares

An Untargeted Metabolomics Approach on Carfilzomib-Induced Nephrotoxicity
por: Barla, Ioanna, et al.
Publicado: (2022)

Mineralocorticoid Receptor Pathway Is a Key Mediator of Carfilzomib-induced Nephrotoxicity: Preventive Role of Eplerenone
por: Efentakis, Panagiotis, et al.
Publicado: (2022)

Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib
por: Efentakis, Panagiotis, et al.
Publicado: (2020)

Elucidating Carfilzomib’s Induced Cardiotoxicity in an In Vivo Model of Aging: Prophylactic Potential of Metformin
por: Efentakis, Panagiotis, et al.
Publicado: (2021)

Daratumumab May Attenuate Cardiac Dysfunction Related to Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma: A Prospective Study
por: Terpos, Evangelos, et al.
Publicado: (2021)

Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma
por: Gavriatopoulou, Maria, et al.
Publicado: (2020)

Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients
por: Fotiou, Despina, et al.
Publicado: (2020)

The extended 4-year follow-up results of the ELOQUENT-2 trial
por: Gavriatopoulou, Maria, et al.
Publicado: (2019)

IMiDs for myeloma induced renal impairment
por: Gavriatopoulou, Maria, et al.
Publicado: (2018)

Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study
por: Terpos, Evangelos, et al.
Publicado: (2021)

Efficacy of Panobinostat for the Treatment of Multiple Myeloma
por: Eleutherakis-Papaiakovou, Evangelos, et al.
Publicado: (2020)

Genetic and Functional Evidence of Complement Dysregulation in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy Compared to Controls
por: Gavriilaki, Eleni, et al.
Publicado: (2022)

Plasma Metabolomic Alterations Induced by COVID-19 Vaccination Reveal Putative Biomarkers Reflecting the Immune Response
por: Dagla, Ioanna, et al.
Publicado: (2022)

Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome
por: Gavriatopoulou, Maria, et al.
Publicado: (2020)

Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma
por: Fotiou, Despina, et al.
Publicado: (2022)

Pathogenesis of bone disease in multiple myeloma: from bench to bedside
por: Terpos, Evangelos, et al.
Publicado: (2018)

How I treat elderly patients with plasma cell dyscrasias
por: Gavriatopoulou, Maria, et al.
Publicado: (2018)

SARS-CoV-2 Vaccines in Patients With Multiple Myeloma
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

TP53 mutations determined by targeted NGS in breast cancer: a case-control study
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021)

Antibody Response after Vaccination for Sars-Cov-2 in Patients with AL Amyloidosis and the Impact of Therapy
por: Kastritis, Efstathios, et al.
Publicado: (2021)

Recovery of Innate Immune Cells and Persisting Alterations in Adaptive Immunity in the Peripheral Blood of Convalescent Plasma Donors at Eight Months Post SARS-CoV-2 Infection
por: Kostopoulos, Ioannis V., et al.
Publicado: (2021)

Serological testing for SARS-CoV-2: Advancements and future challenges
por: Alexopoulos, Harry, et al.
Publicado: (2023)

Clinical usefulness of testing for severe acute respiratory syndrome coronavirus 2 antibodies
por: Alexopoulos, Harry, et al.
Publicado: (2023)

Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2023)

Prevalence of MGCS Among Patients With Monoclonal Gammopathies
por: Theodorakakou, Foteini, et al.
Publicado: (2023)

Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma
por: Terpos, Evangelos, et al.
Publicado: (2018)

Continuing Cancer Therapy through the Pandemic While Protecting Our Patients: Results of the Implementation of Preventive Strategies in a Referral Oncology Unit
por: Liontos, Michalis, et al.
Publicado: (2021)

Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events
por: Tsakiri, Eleni N., et al.
Publicado: (2017)

Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma
por: Papadimitriou, Konstantinos, et al.
Publicado: (2020)

A Molecular Signature of Circulating MicroRNA Can Predict Osteolytic Bone Disease in Multiple Myeloma
por: Papanota, Aristea-Maria, et al.
Publicado: (2021)

P901: DARATUMUMAB, IXAZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA PRE-TREATED WITH A LENALIDOMIDE-BASED REGIMEN: FINAL OUTCOMES OF THE PHASE 2 DARIA STUDY
por: Terpos, Evangelos, et al.
Publicado: (2023)

Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma
por: Terpos, Evangelos, et al.
Publicado: (2013)

Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study
por: Usmani, Saad Z., et al.
Publicado: (2023)

Treatment of Bing–Neel syndrome with first line sequential chemoimmunotherapy: A case report
por: Gavriatopoulou, Maria, et al.
Publicado: (2019)

Patients with Multiple Myeloma and Prior COVID-19 Have Superior Antibody Responses Against Sars-Cov-2 Compared with Fully Vaccinated Myeloma Patients with the BNT162b2 Vaccine
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

Third Dose of the BNT162b2 Vaccine Results in Sustained High Levels of Neutralizing Antibodies Against SARS-CoV-2 at 6 Months Following Vaccination in Healthy Individuals
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2022)

Organ-specific manifestations of COVID-19 infection
por: Gavriatopoulou, Maria, et al.
Publicado: (2020)

P-127: Patients with Multiple Myeloma on treatment with Anti-CD38 or Anti-BCMA agents have a suboptimal humoral response following COVID-19 vaccination
por: Terpos, Evangelos, et al.
Publicado: (2021)

Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2023)

P-161: Oral antivirals ritonavir-nirmatrelvir and molnupiravir are highly effective in patients with multiple myeloma and COVID-19; a singlecenter, prospective study
por: Spiliopoulou, Vassiliki, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kdf3gf347tkt2lg32vluisgd8e